**2.2 Epidemiology**

The prevalence of SCZ is around 0.6% and 1.9% in the U.S. population [33]. Based on insurance claims for the management of SCZ, the yearly prevalence in the U.S. is 5.1 per 1000 lives [34]. The illness prevalence appears identical in men and women, although the onset of symptoms occurs younger in men than in women [35]. Men tend to encounter their initial episode of SCZ in their early 20s, while women commonly encounter their initial episode in their late 20s or early 30s [36].

Study regarding a potential connection between geographical birthplace and the origination of SCZ has given inconsistent outcomes. A cooperative survey by the World Health Organization in 10 countries discovered that SCZ occurred with similar rates throughout the diverse geographically-stratified populations [37].
